Carisma Therapeutics Inc. is a late-stage clinical company which focused on advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's advanced product candidate includes Vicineum(TM). Carisma Therapeutics Inc., formerly known as Sesen Bio Inc., is based in CAMBRIDGE, Mass.
Info & Links
CEO
Steven Kelly
Headquarters
3675 MARKET STREET,SUITE 200 PHILADELPHIA, PA 19104, UNITED STATES
Carisma Therapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
19.46M
Enterprise Value
-6.26M
Enterprise Value/EBITDA(ttm)
0.10
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
0.95
Price to Book(mrq)
--
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
100.00%
Operating Margin(ttm)
-314.78%
Profit Margin(ttm)
-385.98%
Return on Equity(ttm)
-957.20%
Return on Invested Capital(ttm)
-1419.09%
Return on Assets(ttm)
-96.39%
Income Statement
Revenue(ttm)
20.27M
Revenue Per Share(ttm)
0.49
Gross Profit(ttm)
20.27M
EBITDA(ttm)3
-63.37M
Net Income Available to Common(ttm)
-63.80M
Diluted EPS(ttm)
-1.56
Share Statistics
Beta (5Y Monthly)
1.56
52-Week Change
-81.34%
S&P 500 52-Week Change
18.16%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
41.75M
Dividend Yield
0.00%
Float4
36.50M
% Held by Insiders
12.57%
% Held by Institutions
44.27%
Balance Sheet
Total Cash(mrq)
26.88M
Total Cash Per Share(mrq)
0.64
Total Debt(mrq)
1.17M
Total Debt/Equity(mrq)
-10.52%
Current Ratio(mrq)
3.23%
Quick Ratio(mrq)
3.23%
Book Value Per Share(mrq)
-0.27
Cash Flow
Operating Cash Flow Per Share(ytd)
-1.24
Free Cash Flow(ytd)
-51.69M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.